Chart Thread, page-624

First 624 Last

Share
Profile

Follow
Newton999

2,604 Posts.

66

09/03/21

17:01

Post #: 51635530
Share

Originally posted by Hevlet: ↑

@ChinaDragon

I'm not suggestion a take over at this state - its way too early.

My point is more about having something to benchmark to from a valuation perspective.

The biggest issue when Bard1 announced the results of the latest SubB2m tests was no one knew how to value the company given it's all still about potential at this stage.

Everyone knew the results were good but no-one on here knew what it really means - hence lots of speculations and people saying what's this worth etc etc.

So instead of valuing on based revenues, the next best way (like you would in resources) is to look at what other transactions have occurred in a similar space in the market (e.g. compare resource size of other companies or products in the market or research programs).

If you are willing to go on the journey what you can see is that other transactions that have occurred in this space (on projects that are further through the development process) have been done in the multi billions.

Hence you can see the potential that sits here over time.

Don't forget that there will still be further dilution at some point in the journey (so don't do what I'm sure lots of you are doing by saying $11 Billion divided by $250 mil x by my shareholding = I'm a millionaire!) and hopefully they will be able to bring more cornerstone investors into the registry as and when they need it.

As I mentioned Thrive raised over $350 mil to get where they are and Grail raised over $2 Billion. So assuming the science keeps proving itself up additional fundraising is inevitable imho and is actually an important part of the commercialisation process.

At this stage my thoughts are people should stop worrying about every little daily move up and down (unless you are a ST trader) and just watch the process roll through.

My bet is when they announce hopefully this month the Bard1 ovarian results (see their presentations) people will still confuse it with the SubB2m results just released last month.

The Bard1 results will be Ovarian or Breast Cancer specific results.

SubB2m is a Pan Cancer marker (i.e. do you have some form of cancer or not).

This forum will be filled up with lots of comments of confusion saying 'but I thought they had results of 100% / 100%' when actually its a completely different 'shot on goal' as mentioned a few times by the company. (at least that's my prediction).

The real kicker for me will be whether over time they are able to combine the SubB2m results with the Bard1 tests (or others like a PSA test for prostate etc).

That's in my mind when the real money will be made.

I may be right - may be wrong.

Good luck all.

Cheers

Hevlet

Expand

What is the difference between the SubB2m and the NET technology?

Thanks, GLTAH

BD1 Price at posting: $4.00 Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

BC8

'Big Sarah gets bigger' as Black Cat expands with acqusitions, tenement pegging

AII

Inside the depths of Panasqueira: A legacy carved in rock

ORD

Ordell cracks into gold mineralisation 'very close to surface' at McNabs East

CC9

Chariot buys into 'highly prospective' hard-rock lithium JV in Nigeria

First 624 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 37.5¢		Change 0.015(4.17%)		Mkt cap ! $41.30M

Open	High	Low	Value	Volume
37.5¢	38.0¢	36.5¢	$33.85K	90.90K

Buyers (Bids)

No.	Vol.	Price($)
2	9088	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
37.5¢	7107	1

View Market Depth

No.	Vol.	Price($)
2	9088	0.370
1	893	0.365
2	20893	0.360
2	18000	0.355
8	77506	0.350

Price($)	Vol.	No.
0.375	7107	1
0.380	353	1
0.385	893	1
0.390	4693	2
0.400	13384	3

Last trade - 12.16pm 10/07/2025 (20 minute delay)

IIQ (ASX) Chart

Chart Thread, page-624

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

'Big Sarah gets bigger' as Black Cat expands with acqusitions, tenement pegging

Inside the depths of Panasqueira: A legacy carved in rock

Ordell cracks into gold mineralisation 'very close to surface' at McNabs East

Chariot buys into 'highly prospective' hard-rock lithium JV in Nigeria

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Chart Thread, page-624

Top Stories

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

'Big Sarah gets bigger' as Black Cat expands with acqusitions, tenement pegging

Inside the depths of Panasqueira: A legacy carved in rock

Ordell cracks into gold mineralisation 'very close to surface' at McNabs East

Chariot buys into 'highly prospective' hard-rock lithium JV in Nigeria

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News